Trials / Completed
CompletedNCT00206219
Head and Neck Phase III Iressa Versus Methotrexate Refractory: Iressa Versus Methotrexate (IMEX)
A Phase III Randomised, Stratified, Parallel-Group, Multi-Centre, Comparative Study of ZD1839 (Iressa®) 250 Mg and 500 Mg Versus Methotrexate for Previously Treated Patients With Squamous Cell Carcinoma of the Head and Neck
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 477 (planned)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is to compare ZD1839 (250mg and 500mg) versus methotrexate in head and neck cancer in terms of overall survival.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Gefitinib | |
| DRUG | methotrexate |
Timeline
- Start date
- 2003-11-01
- Primary completion
- 2007-09-01
- Completion
- 2007-09-01
- First posted
- 2005-09-21
- Last updated
- 2011-01-27
Locations
109 sites across 25 countries: United States, Argentina, Australia, Belgium, Brazil, Canada, Croatia, Czechia, Estonia, Greece, India, Israel, Italy, Latvia, Lithuania, Malaysia, Netherlands, Norway, Russia, Slovenia, South Africa, Spain, Sweden, Thailand, United Kingdom
Source: ClinicalTrials.gov record NCT00206219. Inclusion in this directory is not an endorsement.